Abbott Laboratories and WeightWatchers have partnered to give people living with diabetes more insight into their condition.

The initiative integrates WeightWatchers’ diabetes-specific weight management program with Abbott’s FreeStyle Libre continuous glucose monitoring (CGM) products. It’s designed to make critical information available via mobile devices so that people with diabetes can make healthy adjustments to their diets. Users will be able to view their glucose data alongside information derived from the WeightWatchers program. 

While the partnership will initially focus on the U.S. market, Chris Scoggins, VP of commercial operations and marketing in Abbott’s diabetes care division, said the company hopes to expand its scope in the future.

He added that diabetes is a “complex chronic condition” requiring several different treatments in addition to CGM, including medication, insulin, diet and exercise.

“We recognize that CGMs are only one piece of the diabetes care puzzle. That’s where the power of partnership comes in,” Scoggins explained. “We are partnering with insulin delivery, digital coaching/wellness and technology leaders to bring new advanced solutions that simplify and make it possible for people to spend less time thinking about diabetes and more time living.”

The partnership announcement was released during a stretch when diabetes has been in healthcare headlines, both on the political and business fronts.

Last week, Senate Republicans voted down a $35 price cap on insulin as part of the Inflation Reduction Act. However, Senate Majority Leader Chuck Schumer said he intends to hold another vote on the cap in the fall. 
In mid-July, Vertex Pharmaceuticals announced that it would buy ViaCyte, a private biotech centered on developing therapies for type 1 diabetes.